

International Journal of Bacteriology & Parasitology

Batabyal B and Himanshu. Int J Bacteriol Parasitol: IJBP-105.

DOI: 10.29011/IJBP-105.000005

Research Article

Commonly Use of Oral Antibiotics Resistance in Children Aged 1 To 12 Years with UTIs an Increasing Problem

Biswajith Batabyal*, Himanshu

Department of Microbiology, Om Parkash Jogender Singh University, Rajasthan, India

*Corresponding author: Biswajith Batabyal, Department of Microbiology, Om Parkash Jogender Singh University, Rajasthan, India. Tel: +919830077613; Email: biswajit.batabyal@gmail.com

Citation: Batabyal B, Himanshu (2018) Commonly Use of Oral Antibiotics Resistance in Children Aged 1 To 12 Years with UTIs an Increasing Problem. Int J Bacteriol Parasitol: IJBP-105. DOI: 10.29011/IJBP-105.000005

Received Date: 01 March, 2018; **Accepted Date:** 15 March, 2018; **Published Date:** 26 March, 2018

Abstract

Background: Urinary Tract Infections (UTIs) are counted among the most common infections in children. Most commonly, members of Enterobacteriaceae, particularly urinary pathogenic strains of *E. coli* and *Enterobacter aerogenes* are the primary causative organisms of UTIs in different parts of the world. In spite of the availability and use of the antimicrobial drugs, UTIs caused by bacteria have been showing increasing trends. Antibiotics are a mainstay in the treatment of bacterial infections, though their use is a primary risk factor for the development of antibiotic resistance. Antibiotic resistance is a growing problem in pediatric urology as demonstrated by increased urinary pathogen resistance. The extensive and inappropriate use of antimicrobial agents has invariably resulted in the development of antibiotic resistance which, in recent years, has become a major problem worldwide. Increasing antibiotic resistance among urinary pathogens to commonly prescribed drugs has become a global reality today. Complex pediatric patients with histories of hospitalizations, prior antibiotic exposure and recurrent UTIs are also at high risk for acquiring UTIs due to Extended Spectrum Beta-Lactamase (ESBL) producing organisms. Data regarding the impact of in vitro antibiotic susceptibility testing interpretation on UTI treatment outcomes is lacking. The resistance of bacteria causing Urinary Tract Infection (UTI) to commonly prescribed antibiotics is increasing both in developing as well as in developed countries. Resistance has emerged even to more potent antimicrobial agents.

Objective: The present study was undertaken to report the commonly use of current antibiotic resistance pattern among common bacterial urinary pathogens isolated.

Methodology and Results: A total of 512 urine samples were collected from outpatients of age between 1 to 12 years of both sex of children at Serum Analysis Center Pvt. Ltd. [Referral Laboratory], Howrah, West Bengal, India between December 2016 to November 2017. The urine samples were cultured on HiCrome UTI Agra media and Eosin Methylene Blue Agar media [EMB] and the bacterial isolates were identified by gram staining and conventional biochemical methods. The bacterial isolates recovered of commonly use of oral antibiotics were tested against Amoxicillin/clavulanate, Cefixime, Cefpodoxime, Cefprozil, Cephalexin and Co-trimoxazole (Trimethoprim/sulfamethoxazole) using Kirby Bauer disk diffusion method according to the current National Committee for Clinical Laboratory Standards (NCCLS) guidelines.

Among the 512 urine samples examined (1 to 12 years of children), included 276 (54.0%) in Male child and 236 (46.0%) in Female child and 220 (42.9%) of urinary pathogens are isolated. The bacteria were isolates 104 (37.7%) of male child and 116 (49.2%) of female child. In patient of male child, 50% of *E. coli*, 34.6% of *Klebsiella pneumoniae*, 15.4% of others gram negative bacilli and 52.0% Extended- spectrum Beta Lactamase (ESBL) stains were isolates. In patient of female child, 72.4% of *E. coli*, 20.7% of *Klebsiella pneumoniae*, 6.9% of others gram negative bacilli and 58.7% Extended- Spectrum Beta lactamase (ESBL) stains were isolates. Resistance rates of *E. coli* (1 to 12 years of children) isolates were 83.8% to Amoxicillin/clavulanate, 70.5%

to Cefixime, 89.7% to Cefpodoxime, 80.8% to Cefprozil, 89.8% of Cefalexin and 63.2% to Co-trimoxazole.

Resistance rates of *Klebsiella pneumoniae* (1 to 12 years of children) isolates were 66.7% to Amoxicillin/clavulanate, 43.3% to Cefixime, 90% to Cefpodoxime, 76.6% to Cefprozil, 80% to Cefalexin and 50% to Co-trimoxazole. Resistance rate of Other gram-negative bacilli (1 to 12 years of children) isolates were 75% to Amoxicillin/clavulanate, 33.4% to Cefixime, 91.6% to Cefpodoxime, 91.6% to Cefprozil, 91.6% to Cefalexin and 41.7 % to Co-trimoxazole.

Conclusion: Increasing antibiotic resistance trends indicate that it is imperative to rationalize the use of antimicrobials in the community and also use these conservatively. It is concluded that the clinical isolates have started developing resistance against commonly use antibiotics due to its irrational and inappropriate use. Continuous surveillance is crucial to monitor the antimicrobial resistance of pathogens. Finally, we suggest that empirical antibiotic selection should be based on knowledge of the local prevalence of bacterial organisms and antibiotic sensitivities rather than on universal guidelines.

Keywords: Antibiotic Resistance; Oral Antibigram; Paediatrics; Urinary Tract Infections

Introduction

Urinary Tract Infections (UTIs) are amongst the most common infections encountered in clinical practice [1]. Acute Urinary Tract Infections are relatively common in children, with 8 percent of girls and 2 percent of boys having at least one episode by seven years of age and between 30% and 40% will have another episode within two years [2-3]. The most common pathogen is *Escherichia coli*, accounting for approximately 85 percent of Urinary Tract Infections in children. Renal parenchymal defects are present in 3 to 15 percent of children within one to two years of their first diagnosed Urinary Tract Infection. Clinical signs and symptoms of a Urinary Tract Infection depend on the age of the child, but all febrile children two to 24 months of age with no obvious cause of infection should be evaluated for Urinary Tract Infection (with the exception of circumcised boys older than 12 months). Evaluation of older children may depend on the clinical presentation and symptoms that point toward a urinary source (e.g., leukocyte esterase or nitrite present on dipstick testing; pyuria of at least 10 white blood cells per high-power field and bacteriuria on microscopy).

A Urinary Tract Infection (UTI) is one of the most important causes of morbidity and mortality in the developing countries like India. Several studies have demonstrated that the geographical variability of pathogen occurrence in case of UTI among inpatients and outpatient populations is limited by the predominance of gram-negative species usually Enterobacteriaceae and particularly *E. coli* and *Enterobacter* spp. in various regions of the world [4-5].

Antimicrobial Resistance (AMR) is a global growing issue and several reports suggest that it is an increasing problem of phenomenal proportions, affecting both developed and developing countries [6]. AMR is considered as a natural phenomenon for the survival of micro-organism. Therefore, it is imperative to slow the rate of development of AMR to a level that maintains the usefulness of the antimicrobials [6]. Accurate determination of bacterial susceptibility to antibiotics is essential for the successful

management of bacterial infections and comparative analysis of antimicrobial agents. Public health officials and clinicians monitor drug resistance through appropriate reporting of the results from susceptibility tests and this can be achieved using a number of techniques, including the disk diffusion method, the broth dilution assay and the E tests [7]. As antibiotic resistance reduces treatment efficacy, it is a time to consider routine susceptibility testing to guide individual patient treatment and surveillance of antibiotic resistance [8].

Antibiotic	Dosing	Common Adverse Effects
Amoxicillin/clavulanate (Augmentin)	25 to 45mg/kg per day, divided every 12 hours	Diarrhea, nausea/vomiting, rash
Cefixime (Suprax)	8 mg/kg every 24 hours or divided every 12 hours	Abdominal pain, diarrhea, flatulence, rash
Cefpodoxime	10 mg/kg per day, divided every 12 hours	Abdominal pain, diarrhea, nausea, rash
Cefprozil (Cefzil)	30 mg/kg per day, divided every 12 hours	Abdominal pain, diarrhea, elevated results on liver function tests, nausea
Cephalexin (Keflex)	25 to 50 mg/kg per day, divided every 6 to 12 hours	Diarrhea, headache nausea/vomiting, rash
Trimethoprim/sulfamethoxazole (Bactrim, Spectra)	8 to 10 mg/kg per day, divided every 12 hours	Diarrhea, nausea/vomiting, photosensitivity, rash

Table 1: Antibiotics commonly used to treat Urinary Tract Infections in Children.

The present study was undertaken to assess the commonly use of current oral antibiotics resistance pattern in the common urinary pathogens isolated in children of age group 1 to 12 years. The risk assessment was also performed to determine the factors responsible for the emergence of commonly use of oral antibiotics

resistance in common bacterial urinary pathogens.

Materials and Methods

Study Population, Design and Setting

The current study was conducted in the Department of Microbiology, Serum Analysis Centre Pvt. Ltd. (Referral Laboratory). Howrah, West Bengal, India from December 2016 to November 2017.

Patient Evaluation

A prospective analysis was done on 512 of outpatients. All patients were within ages 1 to 12 of children, comprising of both male and female. All samples received consisted 276 of male child and 236 of female child.

Categories Age Group

- Preschool aged Children: 1to 5 Years.
- School aged Children: >5 to 12 Years.

Collection of Urine Sample:

Early morning mid-stream urine samples were collected using sterile, wide mouthed container with screw cap tops [9]. On the urine sample bottles were indicated name, age, sex and time of collection along with requisition forms.

Sample Processing

A calibrated sterile micron wire loop for the semi-quantitative method was used for the plating and it has a 4.0 mm diameter designed to deliver 0.01 ml. A loopful of the well mixed urine sample was inoculated on HiCrome UTI Agar media and EMB (Eosin Methylene Blue) Agar media. The plate was incubated aerobically at 37°C for overnight. The plates were then examined macroscopically and microscopically for bacterial growth. The bacterial colonies were counted and multiplied by 100 to give an estimate of the number of bacteria present per millilitre of urine. Culture results were interpreted according to the standard criteria and a growth of $> 10^5$ colony forming unit [CFU]/ml was considered as significant bacteriuria [10]. The urine samples were analysed bacteriological using the methods [9, 11, 12].

Identification of Isolates

The isolates were identified using colony morphology, Gram staining, Motility test, Indole test, Citrate test (Simmons Citrate Agar media), Urease test (Urease Agar media + 40% Urea), Triple Sugar Iron Agar media, ONPG (Ortho-nitrophenyl beta-D-galactopyranoside) and Oxidase test [9, 12].

Antimicrobial Susceptibility Testing

All isolates were tested for antimicrobial susceptibility on Muller Hinton Agar by the standard Bauer et al. disc diffusion method [13] recommended by the Clinical and Laboratory Standards institute (CLSI) [14]. Antibiotic agents (disks) were obtained from Hi Media Laboratories, Pvt. Ltd, Mumbai. Appropriate quality control strains were used to validate the results of the antimicrobial disk. In this section of the study, bacterial isolates recovered of commonly use of oral antibiotics were tested against Amoxicillin/clavulanate (20/10 mcg), Cefixime (5 mcg), Cefpodoxime (10 mcg), Cefprozil (30 mcg), Cephalexin (30 mcg) and Co-trimoxazole (Trimethoprim/sulfamethoxazole) (1.25/23.75 mcg). *E. coli*, ATCC 25922 and *Pseudomonas aeruginosa*, ATCC 27853 was used as quality control strains [12].

Extended-spectrum Beta-lactamase (ESBL) detection by the CLSI phenotype method

The CLSI ESBL confirmatory test with cefotaxime (30mcg) and Cefotaxime/Clavulanic acid (30+10 mcg) were performed for all isolates using the disc diffusion method on Mueller-Hinton Agar plates. Susceptibility test results were interpreted according to criteria established by the CLSI [15].

Results

For the twelve months of this study, 512 urine samples were received and cultured. There were 276 (54.0%) male child and 236 (46.0%) female child giving a total of 512 children who enrolled in this study. Their age ranged from 1 to 12 years. Among the cultures screened, bacteriuria of 10^5 cfu/ml of urine was found in 220 (42.9%) of the samples. A total of 292 (57.0%) of the urine samples were culture negative. 104 (37.7%) were isolated from male child and 116 (49.2%) from female child.

Age Group	Total Population	Male child	Female child
1 to 12 years	512	276 (54.0%)	236 (46.0%)
1 to 5 years	312	170 (54.5%)	142 (45.5%)
>5 to 12 years	200	106 (53.0%)	94 (47.0%)

Table 2: Different age groups of total samples.

Age Group	Total Population	Positive culture	Negative culture
1 to 12 years	512	220 (42.9 %)	292 (57.0%)
1 to 5 years	312	148 (47.4%)	164 (52.6%)
>5 to 12 years	200	72 (36.0%)	128 (64.0%)

Table 3: Prevalence of UTI in different age groups.

Age Group	Total Population in Male child	Positive culture in Male child	Total Population in Female child	Positive culture in Female child
1 to 12 years	276	104 (37.7%)	236	116 (49.2%)
1 to 5 years	170	74 (43.6%)	142	74 (52.2%)
>5 to 12 years	106	30 (28.3%)	94	42 (44.7%)

Table 4: Prevalence of UTI in different age groups with Male and Female child.

Pathogens	Male child [No.: 104]	Female child [No.:116]
<i>E. coli</i>	52 (50.0%)	84 (72.4%)
<i>Klebsiella pneumoniae</i>	36 (34.6%)	24 (20.7%)
Others Gram Negative Bacilli	16 (15.4%)	8 (6.9%)
ESBL Stain	54 (52.0%)	68 (58.7%)

Table 5: Prevalence of pathogens isolated on urine culture with age group of 1 to 12 years.

Pathogens	Male child [No.: 74]	Female child [No.: 74]
<i>E. coli</i>	36 (48.6%)	54 (73.0%)
<i>Klebsiella pneumoniae</i>	26 (35.2%)	14 (18.9%)
Others Gram Negative Bacilli	12 (16.2%)	06 (8.1%)
ESBL Stain	40 (54.0%)	44 (59.5%)

Table 6: Prevalence of pathogens isolated on urine culture with age group of 1-5 years.

Pathogens	Male child [No.: 30]	Female child [No.: 42]
<i>E. coli</i>	16 (53.3%)	30 (71.4%)
<i>Klebsiella pneumoniae</i>	10 (33.3%)	10 (23.8%)
Others Gram Negative Bacilli	04 (13.4%)	02 (4.8%)
ESBL Stain	14 (46.7%)	24 (57.2%)

Table 7: Prevalence of pathogens isolated on urine culture with age group of >5 to 12 years.

Total Isolates: 136

Antibiotics	R (No.)	R (%)	S (No.)	S (%)
Amoxicillin/Clavulanic acid	114	83.8	22	16.2
Trimethoprim/Sulfamethoxazole	86	63.2	50	36.8

Cefixime	96	70.5	40	29.5
Cefpodoxime	122	89.7	14	10.3
Cefprozil	110	80.8	26	19.2
Cefalexin	122	89.8	14	10.2

Table 8: Percentage of Resistance & Susceptibility of isolated *Escherichia coli* to tested commonly use of oral antibiotics: [1-12 years].




Figure 1: Pattern of *Escherichia coli* Resistance and Sensitivity.

Total Isolates: 60

Antibiotics	R (No.)	R (%)	S (No.)	S (%)
Amoxicillin/Clavulanic acid	40	66.7	20	33.3
Trimethoprim/Sulfamethoxazole	30	50.0	30	50.0
Cefixime	26	43.3	34	56.7
Cefpodoxime	54	90.0	06	10.0
Cefprozil	46	76.6	14	23.4
Cefalexin	48	80.0	12	20.0

Table 9: Percentage of Resistance and Susceptibility of isolated *Klebsiella pneumoniae* to tested commonly use of oral antibiotics: [1 to 12 years].




Figure 2: Pattern of *Klebsiella pneumoniae* Resistance and Sensitivity.

Total Isolates: 24

Antibiotics	R (No.)	R (%)	S (No.)	S (%)
Amoxicillin/Clavulanic acid	18	75.0	06	25.0
Trimethoprim/Sulfamethoxazole	10	41.7	14	58.3
Cefixime	08	33.4	16	66.6
Cefpodoxime	22	91.6	02	08.4
Cefprozil	22	91.6	02	08.4
Cefalexin	22	91.6	02	08.4

Table 10: Percentage of Resistance & Susceptibility of isolated others Gram Negative Bacilli to tested commonly use of oral antibiotics: [1-12 years].




Figure 3: Pattern of Others Gram Negative Bacilli Resistance & Sensitivity.

Total Isolates: 90

Antibiotics	R (No.)	R (%)	S (No.)	S (%)
Amoxicillin/Clavulanic acid	80	88.9	10	11.1
Trimethoprim/Sulfamethoxazole	58	64.4	32	35.6
Cefixime	62	68.8	28	31.2
Cefpodoxime	80	88.8	10	11.2
Cefprozil	70	77.8	20	22.2
Cefalexin	82	91.1	08	08.9

Table 11: Percentage of Resistance & Susceptibility of isolated *Escherichia coli* to tested commonly use of oral antibiotics: [1-5 years].




Figure 4: Pattern of *Escherichia coli* Resistance & Sensitivity.

Total Isolates: 40

Antibiotics	R (No.)	R (%)	S (No.)	S (%)
Amoxicillin/Clavulanic acid	30	75.0	10	25.0
Trimethoprim/Sulfamethoxazole	20	50.0	20	50.0
Cefixime	20	50.0	20	50.0
Cefpodoxime	36	90.0	04	10.0
Cefprozil	34	85.0	06	15.0
Cefalexin	34	85.0	06	15.0

Table 12: Percentage of Resistance & Susceptibility of isolated *Klebsiella pneumoniae* to tested commonly use of oral antibiotics: [1 to 5 years].




Figure 5: Pattern of *Klebsiella pneumoniae* Resistance & Sensitivity.

Total Isolates: 18

Antibiotics	R (No.)	R (%)	S (No.)	S (%)
Amoxicillin/Clavulanic acid	14	77.8	04	22.2
Trimethoprim/Sulfamethoxazole	08	44.5	10	55.5
Cefixime	07	38.8	11	61.2
Cefpodoxime	16	88.8	02	11.2
Cefprozil	16	88.8	02	11.2
Cefalexin	16	88.8	02	11.2

Table 13: Percentage of Resistance & Susceptibility of isolated others Gram Negative Bacilli to tested commonly use of oral antibiotics: [1-5 years].




Figure 6: Pattern of Others Gram Negative Bacilli Resistance & Sensitivity.

Total Isolates: 46

Antibiotics	R (No.)	R (%)	S (No.)	S (%)
Amoxicillin/Clavulanic acid	34	74.0	12	26.0
Trimethoprim/Sulfamethoxazole	28	60.8	18	39.2
Cefixime	34	74.0	12	26.0
Cefpodoxime	42	91.3	04	08.7
Cefprozil	40	87.0	06	13.0
Cefalexin	40	87.0	06	13.0

Table 14: Percentage of Resistance & Susceptibility of isolated *Escherichia coli* to tested commonly use of oral antibiotics: [>5 to 12 years].




Figure 7: Pattern of *Escherichia coli* Resistance & Sensitivity.

Total Isolates: 20

Antibiotics	R (No.)	R (%)	S (No.)	S (%)
Amoxicillin/Clavulanic acid	10	50.0	10	50.0
Trimethoprim/Sulfamethoxazole	10	50.0	10	50.0
Cefixime	06	30.0	14	70.0
Cefpodoxime	18	90.0	02	10.0
Cefprozil	12	60.0	08	40.0
Cefalexin	14	70.0	06	30.0

Table 15: Percentage of Resistance & Susceptibility of isolated *Klebsiella pneumoniae* to tested commonly use of oral antibiotics: [>5 to 12 years].




Figure 8: Pattern of *Klebsiella pneumoniae* Resistance & Sensitivity.

Total Isolates: 06

Antibiotics	R (No.)	R (%)	S (No.)	S (%)
Amoxicillin/ Clavulanic acid	04	66.6	02	33.4
Trimethoprim/ Sulfamethoxazole	02	33.4	04	66.7
Cefixime	01	16.6	05	83.4
Cefpodoxime	05	83.3	01	16.7
Cefprozil	05	83.3	01	16.7
Cefalexin	05	83.3	01	16.7

Table 16: Percentage of Resistant & Susceptibility of isolated Others Gram Negative Bacilli to tested commonly use of oral antibiotics: [>5 to 12 years].




Figure 9: Pattern of Others Gram Negative Bacilli Resistance & Sensitivity.

Discussion

Urinary tract infections are common, potentially serious infection of childhood. Community acquired Urinary Tract Infections (UTI) cause significant illness in the first 2 years of life and are considered as common disease in school and pre-school children [16-18]. Urinary Tract Infection in children is a significant source of morbidity. It is generally agreed that children with UTI require further investigation and continuing urinary surveillance to minimize future complications.

Escherichia coli is the most common cause of Urinary Tract Infection [19]. Other urinary pathogens include *Klebsiella pneumoniae*, *Enterobacter aerogenes*, *Citrobacter* sp., *Pseudomonas aeruginosa*, *Proteus* sp., *Enterococcus faecalis* [19-21]. Our findings are consistent with these reports. In our study confirmed *Escherichia coli* are major urinary pathogen and Urinary Tract Infection was more common among females than male children.

The Results of the present study indicate a high incidence of microbial resistance to commonly use of oral antibiotics of Amoxicillin/clavulanic acid, Co-trimoxazole, Cefixime, Cefpodoxime, Cefprozil, Cefalexin in Urinary Tract Infections among children [Table 8-16] and suggest the physicians to be cautious about treatment with antibiotics. Knowledge of the local antibiotic resistance helps in guiding antibiotic choice.

Extended-Spectrum Beta-Lactamases (ESBL) are enzymes that confer resistance to most beta-lactam antibiotics, including penicillin, cephalosporins and the monobactam aztreonam. Infections with ESBL-producing organisms have been associated with poor outcomes. Community and hospital-acquired ESBL-producing Enterobacteriaceae are prevalent worldwide [22]. Reliable identification of ESBL-producing organisms in clinical laboratories can be challenging, so their prevalence is likely underestimated. Carbapenems are the best antimicrobial agent for infections caused by such organisms.

Beta-lactamases are enzymes that open the beta-lactam ring, inactivating the antibiotic. The first plasmid-mediated beta-lactamase in gram-negative bacteria was discovered in Greece in the 1960s. It was named TEM after the patient from whom it was isolated (Temoniera) [23]. Subsequently, a closely related enzyme was discovered and named TEM-2. It was identical in biochemical properties to the more common TEM-1 but differed by a single amino acid with a resulting change in the isoelectric point of the enzyme. These two enzymes are the most common plasmid-mediated beta-lactamases in gram-negative bacteria, including Enterobacteriaceae, *Pseudomonas aeruginosa*, *Haemophilus influenzae* and *Neisseria gonorrhoeae*. TEM-1 and TEM-2 hydrolyze penicillins and narrow spectrum cephalosporins, such as cephalothin or cefazolin. However, they are not effective

against higher generation cephalosporins with an oxyimino side chain, such as cefotaxime, ceftazidime, ceftriaxone, or cefepime. Consequently, when these antibiotics were first introduced, they were effective against a broad group of otherwise resistant bacteria. A related but less common enzyme was termed SHV, because sulphydryl reagents had a variable effect on substrate specificity.

Antibiotic resistance is an important issue affecting public health and rapid detection in clinical laboratories is essential for the prompt recognition of antimicrobial-resistant organisms. Infection-control practitioners and clinicians need the clinical laboratory to rapidly identify and characterise different types of resistant bacteria efficiently to minimise the spread of these bacteria and help to select more appropriate antibiotics. This is particularly true for ESBL-producing bacteria. The epidemiology of ESBL-producing bacteria is becoming more complex with increasingly blurred boundaries between hospitals and the community. *E. coli* that produce CTX-M β lactamases seem to be true community ESBL producers with different behaviours from *Klebsiella* spp, which produce TEM-derived and SHV-derived ESBLs. These bacteria have become widely prevalent in the community setting in certain areas of the world and they are most likely being imported into the hospital setting. A recent trend is the emergence of community-onset bloodstream infections caused by ESBL-producing bacteria, especially CTX-M-producing *E. coli*. These infections are currently rare, but it is possible that, in the near future, clinicians will be regularly confronted with hospital types of bacteria causing infections in patients from the community. β -lactams contribute a measure class of safer antibiotics. They are widely used as broad-spectrum antibiotics for all the type of infections. New generation of antibiotics is predominantly preferred in clinical use. Many newer β -lactams are expected for the clinical use and many new β -lactams are expected in future. There is a better scope, prosperity for the discovery and development of new and safer β -lactams. The structure of β -lactams, their nature, classification, chemistry to be well studied. β -lactams, their mode of action, their bactericidal properties and their future growth is seen with new hopes. In this study, in the age group of 1 to 5 years, ESBL found 54.0% in male child & 59.5% in female child and the age group of >5 to 12 years, ESBL found 46.7% in male child and 57.2% in female child.

This study clearly demonstrates the development of resistance for commonly use of oral antibiotics in children UTI. Different factors are attributable for emergence of resistance mainly include; high consumption of antibiotics, irrational use, incomplete course of therapy and self-medication by patients, leading to the emergence of resistance and even treatment failures. One major cause of self-medication is poverty. India is an under developed country, people are used to treating themselves without obtaining prescriptions from physicians. The present situation is alarming, because it is not long before common antibiotics, an effective

antibiotic would be failed to treat even simple or minor infections. Curtailed follow up of regimen also creates resistance. Generally, patients stop their treatment when they feel slight improvement and the microorganisms start adapting the environment rather than get killed. Government must initiate different educational programs, seminars, workshops in collaboration with the media to make people aware of the consequences of self-medication, especially with broad-spectrum antibiotics. In addition to this, routine antimicrobial susceptibility testing must be timely performed to determine the current status of resistance against antimicrobial agents (MIC, E test, Disk diffusion method). Otherwise therapy failures may occur which increase the cost of the therapy as well as recovery time from the underlying disease.

Conclusion

Antimicrobial resistance is a globally ever-increasing problem. The emergence and spread of antimicrobial resistance are complex and driven by numerous interconnected factors. The principle causes of microbial resistance are inappropriate, irrational, high consumption and profligate use of antibiotics. The use of antimicrobials must be restricted and monitored in order to decline the resistance. The present results in increasing commonly use of oral antibiotic resistance trends in UTI patients in children indicate that it is imperative to rationalize the use of antimicrobials and to use these conservatively. Considering the relatively increase rates of UTI and drug resistance observed in this study, continued local, regional and national surveillance is warranted. Antibiotics should only be issued when prescribed by physicians.

Antibiotic resistance is a growing problem in paediatric urology as highlighted by the significantly increased urinary pathogen resistance to commonly use of oral antibiotics. Poor empiric prescribing practices, lack of urine testing and non-selective use of prophylaxis exacerbate this problem. However, three small changes in practice patterns may curb the growing resistance rates: use of urine testing in order to only treat when indicated and tailor broad-spectrum therapy as able; selective application of antibiotic prophylaxis to patients; and use of local antibiograms, particularly paediatric-specific antibiograms, with inpatient *versus* outpatient data.

This study will provide novel, clinically important information on the diagnostic features of childhood UTI and the cost effectiveness of a validated prediction rule, to help primary care clinicians improve the efficiency of their diagnostic strategy for UTI in children. Regular monitoring is required to establish reliable information about resistance pattern of urinary pathogens for optimal empirical therapy of patients with UTIs. Finally, we suggest that empirical antibiotic selection should be based on the knowledge of local prevalence of bacterial organisms and antibiotic sensitivities rather than on universal guidelines.

Acknowledgement

I would like to thank DR. (MRS.) HIMANSHU of the Department of Microbiology; OPJS University; Churu; Rajasthan; India for critical review of the manuscript and suggestions. I express my sincere thanks to Managing Director of Serum Analysis Centre Pvt Ltd., Howrah-711101, West Bengal, India for granting me permission to work in the department and extending all facilities available.

References

1. Gatermann SG (2007) Bacterial infections of the urinary tract. In: Borriello P, Murray PR, Funke G (ed.). *Topley's and Wilson's microbiology and microbial infections*. (10th edition), Vol.III. Hodder Arnold Publishers, London. Pg. No. 671-683.
2. Larcombe J (1999) Urinary tract infection in children. *BMJ* 319: 1173-1175.
3. Shaw KN, Gorelick M, McGowan KL, Yakscoe NM, Schwartz JS (1998) Prevalence of urinary tract infection in febrile young children in the emergency department. *Pediatrics* 102: e16.
4. Bachur R, Harper MB (2001) Reliability of the urinalysis for predicting urinary tract infections in young febrile children. *Arch Pediatr Adolesc Med* 155: 60-65.
5. Twaij M (2000) Urinary tract infection in children: a review of its pathogenesis and risk factors. *J R Soc Health* 120: 220-226.
6. Sharma R, Sharma CL, Kapoor B (2005) Antibacterial resistance: current problems and possible solutions. *Indian J Med Sci* 59: 120-129.
7. Bonev B, Hooper J, Parisot J (2008) Principles of assessing bacterial susceptibility to antibiotics using the agar diffusion method. *J Antimicrob Chemother* 61: 1295-1301.
8. Nweneka CV, Tapha-Sosse N, Sosa A (2009) Curbing the menace of antimicrobial resistance in developing countries. *Harm Reduct J* 6: 31.
9. Collee JG, Duguid JP, Fraser AG, Marmion BP, Simmons A (1996) Laboratory strategy in diagnosis of infective syndromes. In: Collee JG, Duguid JP, Fraser AG, Marmion BP, Simmons A (ed.). *Mackie and McCarty Practical Medical Microbiology*. (14th edition), Churchill Livingstone, London. Pg. No. 53-94.
10. Cruickshank R, Duguid JP, Marmion BP (1975) Tests for identification of bacteria. In: *Medical Microbiology*. (12th edition), Churchill Livingstone, London. Pg. No. 170-189.
11. Kass EH (1957) Bacteriuria and diagnosis of infections of urinary tract. *AMA Arch Intern Med* 100: 709-714.
12. Monika Cheesbrough (2002) *District laboratory Practice in Tropical Countries*. (2nd Edition), Part-2, Cambridge University Press 132-234.
13. Bauer AW, Kirby WM, Sherris JC, Turck M (1966) Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol* 45: 493-496.
14. CLSI (2009a) *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow aerobically* (8th edition). Approved Standard M07-A8. Wayne, PA: Clinical and Laboratory Standards Institute.
15. CLSI (2009b) *Performance Standards for Antimicrobial Susceptibility Testing*, 20th Informational Supplement M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute.
16. Schlager TA (2003) Urinary tract infections in infants and children. *Infect Dis Clin North Am* 17: 353-365.
17. Wald ER (2004) Cystitis and pyelonephritis. In: Feigen RD, Cherry JD, Demmler GJ, Kaplan SL (ed.). *Textbook of Paediatric Infectious Diseases*. (5th edition), Saunders, Philadelphia. Pg. No. 541-553.
18. Fallahzadeh MH, Alamdarlu HM (1999) Prevalence of urinary tract infection in pre-school febrile children. *Iranian J of Med Sci* 24: 35-39.
19. Esmaeili M (2005) Antibiotics for causative microorganisms of urinary tract infections. *Iranian Journal of Pediatrics* 15: 165-173.
20. Fluit C, Mark J, Franz-Josef S, Jacques A, Renu G, et al. (2000) Antimicrobial resistance among urinary tract infection (UTI) isolates in Europe: results from the SENTRY Antimicrobial Surveillance Program 1997. *Antonie Van Leeuwenhoek* 77: 147-152.
21. Jalali M, Asteraki T, Emami-Moghadam E, Kalantar E (2005) Epidemiological study of asymptomatic Bacteriuria among nursery school children in Ahvaz, Iran. *Afr J Clin Exper Microbiol* 6: 159-161.
22. Ben-Ami R, Rodríguez-Baño J, Arslan H et al. (2009) A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. *Clin Infect Dis* 49: 682-690.
23. Bradford PA (2001) Extended-Spectrum β -Lactamases in the 21st Century: Characterization, Epidemiology and Detection of This Important Resistance Threat. *Clin Microbiol Rev* 14: 933-951.